The Number of Banking Executives Saying New Technologies Will Drive Global Banking Rises by 57% in a Year, Reveals Economist Intelligence Unit Report Released by Temenos
Two-thirds of banking executives believe that new technologies such as AI, machine learning will continue to have the greatest impact on the global banking sector in the next five years, according to a global survey conducted by the Economist Intelligence Unit (EIU) on behalf of Temenos (SIX: TEMN), the banking software company. The new report “Forging new frontiers: advanced technologies will revolutionize banking ” highlights that COVID-19 is likely to accelerate the digital transformation of banks, which already face intense competition from payment players, Big Tech and e-commerce firms.
The report trends will be discussed on the webinar ‘The Future of Digital Banking: Revolution Accelerated” on 25 June, with the CEO and Founder of Varo Money, the EIU and Temenos.
With COVID-19 accelerating the digitization of banking, 45% of banking respondents say their strategic response is to build a ‘true digital ecosystem’ and integrate their self-built digital services and third-party offerings. AI will undoubtedly play a key role in accelerating this digital shift. Over three-quarters (77%) of respondents agree that unlocking value from Artificial Intelligence (AI) will be a key differentiator between winning and losing banks. And improving user experience through greater personalization ranked highest (28%) among the most valuable uses for AI.
The focus is shifting towards enterprise agility with DevOps, which brings together software development and IT operations using modern cloud-based platforms. In fact, 84% of respondents agree that DevOps will drive transformation in core banking, while 81% of banking executives believe a multi-cloud strategy will become a regulatory pre-requisite. The primary focus of banks’ technology investment is on cybersecurity (35%), followed by developing AI platforms such as digital advisors and voice assisted engagement channels (33%), and cloud-based technologies (27%).
Max Chuard, Chief Executive Officer, Temenos, said: “Banks were under huge pressure due to new competitors, ongoing regulation and slowing profit growth – these pressures have intensified as a result of the pandemic. The report highlights that senior banking executives believe that new technologies such as AI will have the greatest impact in banking in the coming years. As the digitization of banking continues, these new technologies can help banks fend off competitors and gain competitive advantage.
“Temenos’ cloud-advanced, AI technology and rich banking functionality can help banks deliver value to their customers in the immediate term and accelerate their digital transformation to build sustainable growth in the future. Trends toward digital banking, cloud and SaaS models will only become more pronounced – in the new normal, the need for modern banking technology will be greater than ever.”
Pete Swabey, Editorial Director EMEA - Thought Leadership, The Economist Intelligence Unit, added: “Retail, corporate and private banks were already under pressure to deploy new technologies quickly and change their cultures in order to compete with big tech firms and payment players and deliver an engaging digital experience. Now, as digital banking surges as a result of the coronavirus crisis, this task is more pressing than ever.”
About the survey
Now in its seventh year, the Economist Intelligence Unit report includes for the first time respondents from commercial and private banks, alongside retail banks. The EIU surveyed 305 global banking executives throughout February and March 2020 about the challenges banks are facing relating to the digitization of the sector, and the strategies they are deploying in response. Almost half of respondents (49%) were at C-Suite level. Respondents came from Europe (25%), North America (24%), Asia-Pacific (18%), Africa and the Middle East (16%), and Latin America (17%).
– Ends –
About Temenos
Temenos AG (SIX: TEMN), headquartered in Geneva, is the world’s leader in banking software, partnering with banks and other financial institutions to transform their businesses and stay ahead of a changing marketplace. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic front office and core banking, payments, fund management and wealth management software products enabling banks to deliver consistent, frictionless customer journeys and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve industry-leading cost-income ratios of 25.2% and returns on equity of 25.0%, 2X better than the industry average. These clients also invest over 53% of their IT budget on growth and innovation versus maintenance, which is 2.5X the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200609005051/en/
Contact information
Media Contacts
Jessica Wolfe
Temenos Global Public Relations
Tel: +1 610 232 2793
Email : press@temenos.com
Alistair Kellie & Andrew Adie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
Email: allnewgatetemenos@newgatecomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LintonPharm Announces Authorization From China Health Authority to Proceed With a Global Phase 3 Trial Evaluating Catumaxomab in Advanced Gastric Cancer15.7.2020 23:30:00 EEST | Press release
LintonPharm Co. Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T-cell engaging bispecific antibodies for cancer immunotherapy, today announced the China National Medical Products Administration (NMPA) authorized the company to proceed with a Phase III trial (clinicaltrials.gov: NCT04222114) for catumaxomab in patients with peritoneal carcinomatosis, a form of advanced gastric cancer that has spread to the tissue that lines the abdominal cavity. The two-stage, multi-center, open-label, randomized, controlled registrational clinical trial will evaluate the safety and efficacy of an intraperitoneal infusion of the bi-specific antibody catumaxomab into the abdominal cavity in patients with peritoneal carcinomatosis. LintonPharm also recently received Clinical Trial Application (CTA) authorization for the same indication from the Taiwan Ministry of Health and Welfare (MOHW) and the Korea Ministry of Food and Drug Safety (MFDS). “We are excited to
Xerox Launches ConnectKey-Enabled AltaLink Digital Workplace Assistant15.7.2020 19:47:00 EEST | Press release
Xerox announced its new Xerox AltaLink® C8100 and Xerox AltaLink B8100 Series multi-function printers (MFPs), that can better support today’s flexible work environment and help companies speed their digital transformation with access to the ConnectKey® ecosystem of apps. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200715005746/en/ The tablet-like user interface allows for easy, familiar interaction or the user can choose to print from their mobile devices. (Photo: Business Wire) In addition to its printing capabilities, the AltaLink 8100 series helps speed workplace digitization with ultra-fast scanning of up to 270 images per minute and Optical Character Recognition that allows clients to extract more value from information. Combined with ConnectKey apps, including connections to the most popular cloud solutions, these printers can support a key area of focus for businesses as they shift from physical to digital enterpri
Bureau Veritas Launches a New Solution to Improve Supply Chain Resilience15.7.2020 18:45:00 EEST | Press release
Bureau Veritas , a world leader in testing, inspection and certification (TIC) services, is launching Supply-R, a solution designed to meet companies’ new challenges relating to supplier network reliability and ensuring business continuity in all circumstances. Organizations learned multiple lessons during the first half of 2020 on the resilience of global supply chains and their ability to face disruptions. There is an urgent need from many companies to reassess their supply chain risk, based on factual data from the field, to make sure that all elements are properly addressed, assessed and visible. Bruno Ferreyra, Executive Vice-President at Bureau Veritas, commented: "Economic globalization means supply chains include more suppliers and intermediaries than before, and they are scattered around the globe. This makes each step, process and stakeholder in the manufacturing chain harder to track. Our goal is to support businesses, mapping out their supply chains to give them complete co
VALBIOTIS Announces the First Patient First Visit in the International Phase II/III REVERSE-IT Clinical Study on TOTUM-63 to Reduce Type 2 Diabetes Risk Factors15.7.2020 18:40:00 EEST | Press release
Regulatory News: VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/SME eligible) a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the First Patient First Visit in the international Phase II/III REVERSE-IT clinical study designed to assess TOTUM-63 for the reduction of Type 2 Diabetes metabolic risk factors. Murielle CAZAUBIEL, member of the Management Board and Director of Development and Medical Affairs at VALBIOTIS, comments: "The first visit of this first subject, a few days after obtaining both ANSM 1 approval and the favorable decision from the CPP 2 , marks the concrete launch of the REVERSE-IT study, the results of which are expected in mid-2022. We are right on schedule and are delighted to be able to enter the operational phase of this major study so quickly. We also welcome the enthusiasm and commitment of all the partner investigation centers." Dr Hans-Juergen WOERLE, Chief Scientific and Medical
Octapharma Reports Positive Data from octagam® Usage in Critically Ill COVID-19 Patients15.7.2020 18:04:00 EEST | Press release
Topline results from a retrospective study in 93 critically ill COVID-19 patients have become available. The data shows that IVIG treatment reduces inflammation, which is associated with poor clinical outcomes and death, and points to an increase in survival, in critically ill COVID-19 patients, when compared to a control group. The study was conducted at the Istanbul University Hospital, Turkey, under the lead of Prof. Dr. Figen Esen. In critically ill COVID-19 patients, the cause of death often implicates an abnormal pulmonary immune response. This abnormal immune response is characterized by high levels of inflammatory markers, which are associated with poor clinical outcomes.1, 2 Acute respiratory distress syndrome (ARDS) and multiorgan failure are major causes of mortality in COVID-19 patients.3 High levels of pro-inflammatory cytokines and chemokines are part of a severe inflammatory response known as a “cytokine storm” which may cause multiple organ dysfunction and ARDS in criti
European Commission approves third nintedanib indication in pulmonary fibrosis115.7.2020 16:34:00 EEST | Press release
Boehringer Ingelheim today announced that the European Commission (EC) has approved an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).1 The approval comes after the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion in May 2020.3 The U.S. Food and Drug Administration (FDA), Health Canada and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) recently approved nintedanib as the first treatment for the same patient population.4,5,6 Interstitial lung diseases encompass a large group of more than 200 disorders that may involve the threat of pulmonary fibrosis – an irreversible scarring of lung tissue that negatively impacts lung function.7 People living with fibrosing ILD can develop a progressive phenotype, leading to lung function decline, deterioration in quality of life and early mortality simila
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom